Sarah Cannon Research Institute | Strategic Alliance Partners

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at more than 200 locations in 20+ states across the U.S. Learn more about our research offerings.

Connect with us:

Latest from Sarah Cannon Research Institute

FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD

August 18, 2025

Podcast

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer

June 02, 2025

Video

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC

June 01, 2025

Video

David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

May 16, 2025

Article

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer

April 16, 2025

Article

Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Dr Hamilton on Treatment Selection After Progression on Frontline CDK4/6 Inhibition in HR+ Breast Cancer

April 10, 2025

Video

Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.

Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy

February 02, 2025

Article

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer

December 20, 2024

Video

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Dr Battiwalla on Limitations to CAR T-Cell Therapy Access in Hematologic Malignancies

October 24, 2024

Video

Minoo Battiwalla, MD, MS, discusses both the benefits and the limitations of treatment with CAR T-cell therapy across hematologic malignancies.

Dr Battiwalla on the Potential Roles of FLT3-ITD and Menin Inhibitors in AML Management

October 21, 2024

Video

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL

September 27, 2024

Video

Minoo Battiwalla, MD, MS, discusses the variety of bispecific antibodies evaluated for patients with NHL, including DLBCL.

Dr McKean on the Efficacy of Fianlimab Plus Cemiplimab in Advanced Melanoma

September 26, 2024

Video

Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.

Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC

September 14, 2024

Article

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

September 11, 2024

Podcast

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast Cancer

August 22, 2024

Video

Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr Battiwalla on Addressing Unmet Needs in Multiple Myeloma

August 05, 2024

Video

Minoo Battiwalla, MD, discusses remaining unmet needs for patients with multiple myeloma and potential strategies being explored to address these needs.

Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 16, 2024

Video

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer

July 16, 2024

Video

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies

July 11, 2024

Article

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.

Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 09, 2024

Video

Key opinion leaders discuss other clinical trials, including the EMERALD study, and targeted therapies for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in later lines of therapy.